Stock Price & Analysis

The S1 support level for CNTA Stock is $14.91 ,The R1 resistant level for CNTA Stock is $16.79.

As of the end of day on 2025-03-04, the price of CNTA Stock was $16.33.

The target price for CNTA Stock according to analyst rating is 34.00, with the highest price target at 35.00 and the lowest at 33.00. Analysts have a Strong Buy rating on CNTA Stock overall.

The market cap of CNTA is $2.2B.

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company's advanced product candidate, SerpinPC, is a subcutaneously administered inhibitor of activated protein C (APC) being developed as a potential treatment for hemophilia. Leveraging its LockBody technology, it is developing an approach to selectively drive potent effector function activity, such as CD47 or CD3, into the tumor microenvironment (TME) while avoiding systemic toxicity. Its first LockBody product candidate, LB101, is a conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody used in solid tumors. Its other programs consist of earlier-stage preclinical assets, including ORX750, an orally administered, selective Orexin Receptor-2 (OX2R) agonist for the treatment of narcolepsy (NT1) with potential expansion into other sleep disorders, and MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH).

CNTA has a total of 76 employees.